Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 10, 2026

Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 3, 2026

Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Seeking Alpha • May 29, 2026

Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy

Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability.

Seeking Alpha • May 21, 2026

Roivant Sciences Q4 Earnings Call Highlights

Roivant Sciences NASDAQ: ROIV executives used the company's fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in dermatomyositis.

MarketBeat • May 20, 2026

Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript

Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript

Seeking Alpha • May 20, 2026

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

BASEL, Switzerland and LONDON and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provided a business update.

GlobeNewsWire • May 20, 2026

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.26.

Zacks Investment Research • May 20, 2026

2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug

Immunovant reports clinically meaningful trial results for its lead drug candidate. That's good news for Roivant Sciences.

Barrons • May 20, 2026

Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why

Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • May 19, 2026